Today's Trend
Bio‑Rad Laboratories, Inc. (NYSE: BIO) is trading lower after its Q1 results and a subsequent outlook cut. Investors are reacting to an EPS miss, a trimmed FY‑2026 revenue outlook and higher trading volume, despite a small revenue beat and healthy margins.
- Revenue/operational positives — Q1 revenue of $592.1M slightly beat the consensus (~$590M) and revenue was up ~1.1% year‑over‑year; the company still shows a strong net margin (~29%). These factors provide some support versus a pure earnings shock. MarketBeat Q1 Release
- Analyst action — Wells Fargo cut its price target from $320 to $290 but kept an "equal weight" rating; the new PT still implies upside versus the current share level, which moderates the negative read on the name. Benzinga
- Full earnings call transcript now available — details on segment drivers, margin commentary and near‑term cadence are in the call and may clarify management's guidance changes for investors. Earnings Call Transcript
- EPS miss — Q1 EPS was $1.89, below consensus (about $1.97) and down from $2.54 a year earlier, a clear earnings disappointment that weighed on sentiment. Zacks
- Guidance cut — Management trimmed its FY‑2026 outlook, issuing revenue guidance of about $2.5B–$2.6B versus consensus nearer the top of that range; the company explicitly lowered its outlook, which is the main driver of the share decline. TipRanks
Bottom line for investors: the stock is down as the market focuses on the EPS miss and the trimmed FY‑2026 outlook. Offsetting factors — a small revenue beat, strong margins and a still‑supportive (if reduced) analyst price target — limit the selloff but don’t erase the near‑term uncertainty. Review management commentary in the earnings call to assess whether the guidance cut reflects temporary headwinds or a more persistent slowdown.